MindImmune Extends Series A to $30M to Advance Inflammation-Focused Alzheimer’s Therapy into the Clinic and Appoints Isaac Stoner as CEO
CAMBRIDGE, Mass.–(BUSINESS WIRE)–MindImmune Therapeutics, a private company developing new treatments targeting the inflammatory drivers of neurodegenerative disease, today announced two major milestones: the closing of a $10.2 million Series A extension, which brings the total…
